MétaCan
Menu
← Back to cohort
Record W2898220308 · doi:10.1093/annonc/mdy292.064

Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

2018· article· en· W2898220308 on OpenAlexaff
Glenwood Goss, Manuel Cobo, Shun Lü, K. Syrigos, K.H. Lee, Erdem Göker, Vassilis Georgoulias, W. Li, Dolores Isla, Alessandro Morabito, Young Joo Min, Andrea Ardizzoni, A. Cseh, Shaun Bender, Enriqueta Felip

Bibliographic record

VenueAnnals of Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsUniversity of Ottawa
Fundersnot available
KeywordsMedicineAfatinibErlotinibOncologyInternal medicineSquamous-cell carcinoma of the lungLungPhases of clinical researchBasal cellClinical trialEpidermal growth factor receptorCancer

Abstract

fetched live from OpenAlex

Background: Primary LL8 data showed significantly improved PFS and OS with afatinib compared with erlotinib as second-line treatment in pts with lung SCC, leading to the approval of afatinib in this setting. As previously reported (data cut-off: Apr 2015), PFS (2.6 vs 1.9 months; HR 0.81 [95% CI 0.69–0.96]; p=0.01), objective response rate (ORR; 5.5 vs 2.8%; p=0.06) and disease control rate (DCR; 50.5 vs 39.5%; p=0.002) were higher with afatinib vs erlotinib. PFS and OS benefits on afatinib appeared even greater for pts with ErbB mutation-positive tumours vs ErbB wild-type tumours.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.054
GPT teacher head0.430
Teacher spread0.376 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueAnnals of Oncology→Same topicLung Cancer Treatments and Mutations→French-language works237,207→